Charttechnik Interneuron Pharm - 500 Beiträge pro Seite

[Wallgrekk]

Nicht nur deswegen ein Kauf: Interneuron


Charttechnik spricht absolut für diesen Wert. Wo man hinsieht nur Kaufsignale.

Der annual Report ist aber um einiges wichtiger. Nachzulesen im Interneuron Forum bei Wallstreet-Online.

[Wallgrekk]

Anscheinend ist der Chart nicht sichtbar....

deshalb hier ein neuer (hoffe, es klappt)

[Wallgrekk]

Kaufsignale, wohin das Auge schaut...!!!

[Wallgrekk]

Ich hatte es vermutet!

Heute eine klasse Rally an der Nasdaq. Ich hoffe ihr werdet den Wert langsam kennenlernen und ihn und seine Produkte zu schätzen wissen.

INTERNEURON PHARM.

WKN 883147

I freu mi!


Wall

[puhvogel]

Du hast recht. Man kann dir nicht vorwerfen, du hättest uns nicht auf IPIC aufmerksam gemacht . Der Lauf von IPIC ist wirklich erstaunlich.
Auf der Pfizer-Konferenz, gab es da Hinweise auf die Pagoclone-Studie?

[puhvogel]

Interneuron Provides Pagoclone Update Following Pfizer Report of Positive Results in Generalized Anxiety Disorder
Company also reports on progress of other clinical-stage products
LEXINGTON, Mass.--(BW HealthWire)--Dec. 18, 2001-- Following a presentation today by Pfizer Inc. at a meeting with investment financial analysts in New York, Interneuron Pharmaceuticals, Inc. (NASDAQ: IPIC - news) reported that patients treated with pagoclone experienced a statistically significant improvement in symptoms of generalized anxiety disorder (GAD), compared to patients treated with placebo. In addition, pagoclone was well tolerated, with no difference from placebo in sedation and no evidence of withdrawal effects.

The six-week clinical trial conducted by Pfizer among 200 patients involved a flexible dose regimen ranging from 0.3 milligrams of pagoclone per day to 1.2 milligrams per day. Entry criteria for patients included Hamilton Anxiety Scale (HAM-A) scores of 18 or higher. Pagoclone patients had a mean 2.3 point lower HAM-A score than placebo patients at week three (p=.033), a mean 3.3 point lower score at week four (p=.006) and a mean 3.2 point lower score at week six (p=.012). At week six, the mean reduction in HAM-A score among pagoclone patients was 11.7 versus 8.5 for placebo.

With respect to side effects, there were no statistically significant differences between pagoclone-treated and placebo-treated patients in sleepiness, as measured by the Stanford Sleepiness Scale, and in withdrawal symptoms, as measured by the Rickel`s Withdrawal Symptom Checklist. In addition, there were no serious clinical or laboratory adverse events among patients treated with pagoclone.

As part of its comprehensive clinical development program for pagoclone, Pfizer is conducting a number of clinical trials, including a Phase III trial in panic disorder, multiple Phase II trials in GAD and multiple clinical pharmacology studies. Pfizer is currently analyzing data from a Phase III trial in panic disorder.

``We are extremely pleased with the results of Pfizer`s study,`` said Glenn L. Cooper, M.D., chairman, president and chief executive officer of Interneuron. ``Pagoclone continues to meet its target product profile as a potentially novel, potent, non-sedating anti-anxiety agent which has not shown withdrawal effects. As the compound progresses in late-stage development, Pfizer, in our view, is the ideal development and commercialization partner.``

Pagoclone is a member of the cyclopyrrolone class of compounds and is a novel GABA (gamma amino butyric acid) receptor agonist in development for the treatment of anxiety disorders. To date, preclinical and clinical testing have shown pagoclone to have promise in the treatment of anxiety disorders. Based on the mechanism of action of pagoclone as a potent agonist of the GABA receptor, the compound has the potential for a rapid onset of anxioloytic effect. Also, preclinical and clinical data suggest the potential to avoid the side effects commonly seen with other drugs currently used to treat anxiety disorders.

Interneuron licensed pagoclone from Rhone-Poulenc Rorer, S.A., now Aventis, S.A., and subsequently conducted several clinical trials prior to licensing worldwide rights to this product to Warner-Lambert Company, now Pfizer, which is responsible for conducting all further clinical development, regulatory review and commercialization of pagoclone.

[Wallgrekk]

@puhvogel:

Ja, und die Resonanz war erstaunlich!

ich werde einige News in extra Threads gleich reinstellen!